BERWYN, Pa., Nov. 26, 2025 /PRNewswire/ -- Mural Health Technologies, Inc., a patient-first clinical trial technology company, today announced the expansion...
Expansion of rhCollagen and BioInk raw material sales in North American territories expected through a new partnership with a U.S.-based logistics...
Subtle's Latest Solutions Set New Benchmarks for AI-powered Acceleration, Image Quality, and OrganizationMENLO PARK, Calif., Nov. 26, 2025 /PRNewswire/ --...
ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a...
ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a...
One Oral Late Breaking Communication and Two Poster PresentationsNEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp....
Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused...
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies...
Key step achieved in advancing HER-096 towards Phase 2 efficacy trial Espoo, Finland, 26 November 2025: Herantis Pharma Plc (“Herantis”),...
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE...
RAMAT GAN, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company...
Scilex closed the second tranche, purchasing a pre-funded warrant exercisable for 263,914,094 shares of Datavault AI Inc. (Nasdaq: DVLT; “Datavault...
The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA)...
Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo...
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United...
The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift...
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology...
Two late-breaking podium presentations and three posters continue to demonstrate cretostimogene as a potential backbone therapy for a broad range...
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on...
PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative...